Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Metadata listed "BIOLIFE SOLUTIONS INC" but the filing text identifies the registrant as Cryomedical Sciences, Inc.)
Reporting Period: Quarterly period ended March 31, 1995 (Nine months ended March 31, 1995 for comparative data).
Business Overview: The Company researches, develops, manufactures, and markets products for hypothermic medicine, primarily the CMS AccuProbe(R) System for cryosurgery. The Company operates with an accumulated deficit and relies on product sales and equity financing.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1995 | Nine Months Ended Mar 31, 1995 | Nine Months Ended Mar 31, 1994 |
|---|---|---|---|
| Revenue | $3,025,520 | $10,921,890 | $9,883,810 |
| Gross Profit | $1,803,098 (60% margin) | $5,879,271 (54% margin) | $4,399,008 (45% margin) |
| Operating Loss | $(648,890) | $(1,450,855) | $(2,338,331) |
| Net Loss | $(645,319) | $(1,418,096) | $(2,316,067) |
| Net Loss Per Share | $(0.03) | $(0.06) | $(0.10) |
| Cash & Equivalents (End of Period) | $1,480,300 (as of Mar 31, 1995) | ||
| Working Capital | |||
| Total Debt (Current + Long Term) | $71,021 (Capital leases and notes payable) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 8% for the three months and 10% for the nine months compared to the prior year, driven by price increases effective in fiscal 1994 and higher warranty revenues from an expanding installed base.
- Margin Expansion: Gross profit margins improved significantly (from 45% to 60% for the quarter) due to standardized manufacturing, cost reductions, and price increases. However, management does not anticipate further margin increases for the fiscal year.
- Expense Management: General and administrative expenses decreased 24% for the quarter due to reduced consulting and investor relations costs. Conversely, R&D expenses rose 24% due to increased research grants and product development.
- Loss Reduction: Net loss decreased by approximately 46% for the quarter and 39% for the nine months compared to the prior year.
- Liquidity: Cash and cash equivalents decreased by $946,167 during the nine-month period, primarily due to operating losses and capital expenditures.
Guidance, Outlook, Risks, and Contingencies
- Cost Reduction Measures: In May 1995, the Company initiated staff reductions of approximately 20%, salary cuts, and reduced leased office space to achieve operating profitability and positive cash flow.
- Regulatory Risks (FDA):
- Urethral Warmer: FDA denied 510(k) clearance in Jan 1994, requiring a Premarket Approval (PMA) or new 510(k) submission. The Company submitted an Investigational Device Exemption (IDE) in April 1994. Sales of the AccuProbe System in urology slowed during the uncertainty but have recovered.
- Promotional Warning: In March 1994, the FDA issued a warning letter regarding promotional materials implying the AccuProbe treats "prostate cancer." The Company agreed to modify materials to comply.
- Reimbursement Uncertainty: Lack of uniform insurance reimbursement (Medicare considers procedures investigational) limits sales growth and probe usage rates. The Company cannot predict when national guidelines will be established.
- Legal Proceedings:
- Securities Class Action: A consolidated suit regarding alleged disclosure failures was partially dismissed in April 1995. Plaintiffs may proceed only on specific disclosure questions regarding the Urethral Warmer in 1992.
- Patent Litigation: Competitor Cryogenic Technology Limited filed suit in April 1995 seeking a declaration of patent invalidity. The Company intends to counterclaim for infringement.
- Capital Needs: Management believes current cash is sufficient for 12 months but expects to pursue short-term financing and possibly additional equity financing in fiscal 1995 and 1996.
Investor Verification Checklist
- Reimbursement Status: Verify current Medicare and private insurer reimbursement policies for urological cryosurgery, as this is the primary constraint on sales volume.
- FDA Clearance Timeline: Confirm the status of the new 510(k) application for the CMS Urethral Warmer and the impact of its approval on urology sales.
- Legal Exposure: Monitor the outcome of the remaining claims in the securities class action and the patent infringement suit filed by Cryotech.
- Cash Burn Rate: Assess the effectiveness of the 20% staff reduction and cost-cutting measures in extending the runway beyond the projected 12 months.
- Probe Utilization: Analyze the trend in single-use probe sales relative to the installed base to gauge actual clinical usage versus inventory stocking.